4-氯-2-甲基-1,7-二氮杂萘 | 61319-98-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 4-氯-2-甲基-1,7-二氮杂萘
• 英文名称: 4-chloro-2-methyl-1,7-naphthyridine
• CAS: 61319-98-0
• 化学式: C₉H₇ClN₂
• 分子量: 178.621
• InChiKey: BTWUWVSDZFRDGY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-氯-2-甲基-1,7-二氮杂萘 在 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 为溶剂， 反应 0.03h， 生成 4-chloro-2,8-dimethyl-1,7-naphthyridine
  参考文献：
  名称：

  [EN] COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS
  [FR] COMPOSÉS ET COMPOSITIONS EN TANT QU'INHIBITEURS DE RÉCEPTEURS DE TYPE TOLL ENDOSOMAL

  摘要：

  本发明涉及4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶基化合物和4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶基化合物（A式），包括这些化合物的药物组合物以及在治疗自身免疫疾病中使用这些化合物的用途。

  公开号：

  WO2018047081A1
• 作为产物：
  描述：

  3-氨基-4-吡啶羧酸 、 丙酮 在 三氯氧磷 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 1.0h， 以35%的产率得到4-氯-2-甲基-1,7-二氮杂萘
  参考文献：
  名称：

  Synthesis of aryl-heteroaryl ureas (AHUs) based on 4-aminoquinoline and their evaluation against the insulin-like growth factor receptor (IGF-1R)

  摘要：

  The insulin-like growth factor receptor (IGF-1R) is a receptor tyrosine kinase (RTK) involved in all stages of the development and propagation of breast and other cancers. The inhibition of IGF-1R by small molecules remains a promising strategy to treat cancer. Herein, we explore SAR around previously characterized lead compound (1), which is an aryl-heteroaryl urea (AHU) consisting of 4-aminoquinaldine and a substituted aromatic ring system. A library of novel AHU compounds was prepared based on derivatives of the 4-aminoquinoline heterocycle (including various 2-substituted derivatives, and naphthyridines). The compounds were screened for in vitro inhibitory activity against IGF-1R, and several compounds with improved activity (3-5 mu M) were identified. Furthermore, a computational docking study was performed, which identifies a fairly consistent lowest energy mode of binding for the more-active set of inhibitors in this series, while the less-active inhibitors do not adopt a consistent mode of binding. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.06.071

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS<br/>[FR] COMPOSÉS ET COMPOSITIONS EN TANT QU'INHIBITEURS DE RÉCEPTEURS DE TYPE TOLL ENDOSOMAL
  申请人：NOVARTIS AG

  公开号：WO2018047081A1

  公开（公告）日：2018-03-15

  The invention disclosed herein relates to 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl compounds of Formula (A), pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of autoimmune diseases.

  本发明涉及4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶基化合物和4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶基化合物（A式），包括这些化合物的药物组合物以及在治疗自身免疫疾病中使用这些化合物的用途。
• Compounds and compositions as inhibitors of endosomal toll-like receptors
  申请人：Novartis AG

  公开号：US10954233B2

  公开（公告）日：2021-03-23

  The invention disclosed herein relates to 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl compounds of Formula (A), pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of autoimmune diseases.

  本发明涉及式（A）的4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶基化合物和4,5,6,7-四氢-2H-吡唑并[4,3-c]吡啶基化合物、包含此类化合物的药物组合物以及此类化合物在治疗自身免疫性疾病中的用途。
• COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS
  申请人：Novartis AG

  公开号：EP3510033A1

  公开（公告）日：2019-07-17
• TW2019/36614
  申请人：——

  公开号：——

  公开（公告）日：——
• Synthesis of aryl-heteroaryl ureas (AHUs) based on 4-aminoquinoline and their evaluation against the insulin-like growth factor receptor (IGF-1R)
  作者：William Engen、Terrence E. O’Brien、Brendan Kelly、Jacinda Do、Liezel Rillera、Lance K. Stapleton、Jack F. Youngren、Marc O. Anderson

  DOI：10.1016/j.bmc.2010.06.071

  日期：2010.8

  The insulin-like growth factor receptor (IGF-1R) is a receptor tyrosine kinase (RTK) involved in all stages of the development and propagation of breast and other cancers. The inhibition of IGF-1R by small molecules remains a promising strategy to treat cancer. Herein, we explore SAR around previously characterized lead compound (1), which is an aryl-heteroaryl urea (AHU) consisting of 4-aminoquinaldine and a substituted aromatic ring system. A library of novel AHU compounds was prepared based on derivatives of the 4-aminoquinoline heterocycle (including various 2-substituted derivatives, and naphthyridines). The compounds were screened for in vitro inhibitory activity against IGF-1R, and several compounds with improved activity (3-5 mu M) were identified. Furthermore, a computational docking study was performed, which identifies a fairly consistent lowest energy mode of binding for the more-active set of inhibitors in this series, while the less-active inhibitors do not adopt a consistent mode of binding. (C) 2010 Elsevier Ltd. All rights reserved.